A5079728020- Fibroblast Growth Factor Research
- Eosinophilic Disorders and Syndromes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- IgG4-Related and Inflammatory Diseases
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Radioactive element chemistry and processing
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Chronic Lymphocytic Leukemia Research
- Chemical Synthesis and Characterization
- Lung Cancer Treatments and Mutations
- Thermal and Kinetic Analysis
- Renal and related cancers
- Cancer Mechanisms and Therapy
- Parathyroid Disorders and Treatments
- Renal cell carcinoma treatment
- BRCA gene mutations in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
Bristol-Myers Squibb (United States)
2025
Taiho Oncology (United States)
2023-2024
University of Michigan
2006-2022
Eli Lilly (United States)
2021-2022
Colorado State University
2006-2020
Michigan Center for Translational Pathology
2020
Michigan Medicine
2018-2019
Pediatrics and Genetics
2019
University of California, San Diego
2004
Temple University
1986
Abstract Purpose: Futibatinib, a covalently-binding inhibitor of fibroblast growth factor receptor (FGFR)1-4 gained approval for the treatment refractory, advanced intrahepatic cholangiocarcinoma (iCCA) harboring an FGFR2 fusion/other rearrangement. An integrated analysis was performed to evaluate safety and provide guidance on management futibatinib-associated adverse events (AEs) in patients with unresectable/metastatic tumors, including iCCA. Patients Methods: Data from three global phase...
We have studied the expression of cell-cycle genes specific to G1 (2A9, 2F1, 4F1, c-myc) and S (histone H3) phases cell cycle in normal malignant human myeloid cycling cells. The levels were determined by measuring amounts RNA blot hybridization assays. Levels compared level S-phase-specific H3 gene. This method can distinguish whether an increased is truly due deregulation or simply reflects increase fraction proliferating In a asynchronous system provided bone marrow cells three donors,...
Abstract Most oral squamous cell carcinomas (OSCC) progress through clinically identifiable stages, starting from premalignant epithelial dysplasia to early invasive OSCC. How cells transform during this process is largely unknown. High monocarboxylate transporter 1 (MCT1; SLC16A1) expression correlated with poor outcomes in OSCC patients, where it thought promote tumor growth by supporting metabolic coupling between cancer and stroma. Because of MCT1 markedly increases the progression...
Infantile fibrosarcoma (IFS) is a rare soft-tissue sarcoma, which classically presents as an aggressive and rapidly enlarging tumor over the distal extremities of children in their first year life. The presence ETV6 NTRK3 gene rearrangement characteristic IFS, can be detected on routine fluorescence situ hybridization (FISH) testing. Patients with IFS typically respond well to surgical resection chemotherapy have overall survival ∼90%. In this report, we outline use integrative clinical...
Brain tumors have become the leading cause of cancer-related mortality in young patients. Novel effective therapies on basis unique biology each tumor are urgently needed. The goal this study was to evaluate feasibility, utility, and clinical impact integrative sequencing genetic counseling children adults with high-risk brain tumors.Fifty-two designated by treating neuro-oncologist be high risk (> 25% chance for treatment failure; mean age, 10.2 years; range, 0 39 years) were enrolled a...
Purpose Evidence-based guidelines inform treatment decisions for patients whom germline genetic information is available. Our real-time tumor sequencing program, which makes precision with cancer, produces matched information, providing a unique opportunity to efficiently implement pharmacogenetics and benefit patients. Methods The database from the Michigan Oncology Sequencing (MI-Oncoseq) program was searched 21 clinically actionable polymorphisms in five cancer-relevant genes: TPMT, DPYD,...
Cancer remains the number one cause of disease-related mortality in children, and despite advances molecular understanding leukemia targeted therapies, refractory a leading death. It therefore is essential to further define features, e.g., FLT3 alterations KMT2A rearrangements, associated with inferior survival early augment or alter therapeutic strategies improve outcomes.To gain insights into genetic drivers predictive aggressive clinical behavior among pediatric patients, we performed...
TPS572 Background: In 2022, the U.S. FDA approved futibatinib, a covalently binding inhibitor of FGFR1–4, for previously treated patients with advanced intrahepatic CCA and FGFR2 fusions/rearrangements. pivotal phase 2 FOENIX-CCA2 study, futibatinib 20 mg once daily (QD) resulted in an objective response rate (ORR) 42% by independent review median duration (DOR) 9.7 months. Futibatinib was tolerable had manageable safety profile. 1 Limited data suggest may also have antitumor activity at...
Abstract Next‐generation sequencing offers opportunities for targeted cancer therapies and may identify pathogenic germline variants. Adolescents’ perception of testing is not well understood. We surveyed 16 adolescents 59 parents regarding motivations, attitudes, knowledge related to paired tumor/germline sequencing. Participants generally had a good objective understanding genetics risk, with scoring higher than adolescents. Nearly all participants were motivated by desire help other...
PURPOSE DICER1 syndrome is a recently described inherited cancer predisposition caused by pathogenic variants in DICER1. With the recent increase integrative clinical sequencing for pediatric patients with cancer, our understanding of continues to evolve, as new and rare are reported. As frequency increases, discussions regarding challenges encountered interpretation results essential continue advance field predisposition. The purpose this work was identify somatic and/or germline patient...
Ataxia-telangiectasia is a rare autosomal recessive neurodegenerative disease characterized by ataxia, radiosensitivity, telangiectases, and increased risk for hematologic malignancies. We present case of female individual diagnosed with T-cell acute lymphocytic leukemia at 13 years subsequently αβ subtype hepatosplenic lymphoma (HSTCL) 20 years. During her diagnostic work up HSTCL, paired tumor-germline sequencing identified diagnosis ataxia-telangiectasia. also describe very refractory...
The ETV6-ABL1 fusion is a rare genetic aberration classified as Philadelphia chromosome-like high-risk B-cell precursor acute lymphoblastic leukemia. We present the case of child with multiply relapsed leukemia in which next-generation sequencing identified this cryptic fusion, undetected by standard testing, resulting sustained clinical response to targetted therapy imatinib. Upon subsequent relapse, repeat an additional aberration, MLL2-ADCY9, possible molecular driver conferring...
<p>Safety analysis populations</p>